Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 14Gastrointestinal 7Thoracic 5CNS 5Myeloid 3Lymphoid 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Other neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Photons × Tumor-Agnostic × 1 year × Clear all
NCT02436941 2026-05-08

Radiation Medicine Patient Registry, Loma Linda University Medical Center

Loma Linda University

Enrolling by invitation
75,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡